Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Leo Rasche, MD, Tobias Meissner, PhD, Grant Gershner, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Owen W. Stephens, Michael Bauer, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4372.

https://doi.org/10.1182/blood.V130.Suppl_1.4372.4372

Published: 2017

Journal Articles

Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma

Blood (2017) 130 (1): 30–34.

https://doi.org/10.1182/blood-2017-03-774422

Published: 2017

Includes: Supplemental data

Journal Articles

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Blood (2016) 128 (22): 3278.

https://doi.org/10.1182/blood.V128.22.3278.3278

Published: 2016

Journal Articles

Spatial-Temporal Genomic Analyses Reveal a Component of "Big Bang" Kinetics in Multiple Myeloma Evolution

Niels Weinhold, PhD, Leo Rasche, MD, Tobias Meissner, PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 239.

https://doi.org/10.1182/blood.V128.22.239.239

Published: 2016

Journal Articles

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

Blood (2016) 128 (13): 1735–1744.

https://doi.org/10.1182/blood-2016-06-723007

Published: 2016

Includes: Supplemental data

Journal Articles

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Blood (2015) 126 (23): 372.

https://doi.org/10.1182/blood.V126.23.372.372

Published: 2015

Journal Articles

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

Tobias Meissner, Anja Seckinger, MD, Kari Hemminki, PhD, Uta Bertsch, MD, Asta Foersti, Mathias Haenel, MD, Jan Duering, Hans-Juergen Salwender, MD, Hartmut Goldschmidt, MD, Gareth J Morgan, MDPhD, Dirk Hose, MD, Niels Weinhold, PhD

Blood (2015) 126 (23): 2996.

https://doi.org/10.1182/blood.V126.23.2996.2996

Published: 2015

Journal Articles

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Blood (2015) 126 (23): 20.

https://doi.org/10.1182/blood.V126.23.20.20

Published: 2015

Journal Articles

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Anja Seckinger, MD, Tobias Meißner, PhD, Uta Bertsch, MD, Hans Salwender, MD, Jan Dürig, MD, Mathias Hänel, MD, Igor W. Blau, MD, Christof Scheid, MD, Katja Weisel, MD, Bernard Klein, PhD, Hartmut Goldschmidt, MD, Dirk Hose, Dr. med. dipl.-phys.

Blood (2013) 122 (21): 1863.

https://doi.org/10.1182/blood.V122.21.1863.1863

Published: 2013

Journal Articles

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Blood (2013) 122 (21): 1847.

https://doi.org/10.1182/blood.V122.21.1847.1847

Published: 2013

Journal Articles

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Blood (2013) 121 (22): 4493–4503.

https://doi.org/10.1182/blood-2012-05-429415

Published: 2013

Includes: Supplemental data

Journal Articles

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Mathias Witzens-Harig, MD, Dirk Hose, MD, PhD, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Anja Seckinger, MD, Heinke Conrad, Bettina Brackertz, Thierry Reme, Brigittte Gückel, Tobias Meissner, Michael Hundemer, Anthony D Ho, MD, Jean-Francois Rossi, MD, PhD, Kai Neben, MD, Helga Bernhard, MD, Hartmut Goldschmidt, MD, Bernard Klein, Philipp Beckhove

Blood (2012) 120 (21): 2942.

https://doi.org/10.1182/blood.V120.21.2942.2942

Published: 2012

Journal Articles

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

Arnold Bolomsky, Dirk Hose, MD, Martin Schreder, MD, Anja Seckinger, MD, Tobias Meißner, Bernard Klein, Daniel Heintel, Sabine Pfeifer, Heinz Ludwig, Niklas Zojer

Blood (2012) 120 (21): 3947.

https://doi.org/10.1182/blood.V120.21.3947.3947

Published: 2012

Journal Articles

Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma,

Tobias Meißner, Anja Seckinger, Thierry Rème, Thomas Hielscher, Thomas Möhler, Kai Neben, MD, Hartmut Goldschmidt, MD, Bernard Klein, Dirk Hose

Blood (2011) 118 (21): 3940.

https://doi.org/10.1182/blood.V118.21.3940.3940

Published: 2011

Journal Articles

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Verena Wagner, Dirk Hose, MD, Anja Seckinger, Ludmila Weitz, MSc, Tobias Meißner, Thierry Reme, Jean-Francois Rossi, MD, PhD, Hartmut Goldschmidt, MD, Alwin Krämer, MD, Bernard Klein, Marc S Raab, MD

Blood (2011) 118 (21): 137.

https://doi.org/10.1182/blood.V118.21.137.137

Published: 2011

Journal Articles

Prognostication by miRNome-Profiling in Multiple Myeloma

Anja Seckinger, Tobias Meißner, Vladimir Benes, Sabine Schmidt, Jonathan Blake, Jürgen Zimmermann, Hartmut Goldschmidt, MD, Bernard Klein, Dirk Hose

Blood (2011) 118 (21): 1822.

https://doi.org/10.1182/blood.V118.21.1822.1822

Published: 2011

Journal Articles

A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis

Dirk Hose, Anja Seckinger, Hartmut Goldschmidt, Tobias Meißner, Blanka Leber, Kai Neben, Jens Hillengass, Uta Bertsch, Bernd Janssen, Bernard Klein, Joe Lewis, Karin Vanderkerken, Christoph Schultes

Blood (2010) 116 (21): 2987.

https://doi.org/10.1182/blood.V116.21.2987.2987

Published: 2010

Journal Articles

Proliferation and Activation Patterns of Naïve, Memory and Regulatory T Cells in Patients with Multiple Myeloma During Thalidomide, Interferon-α and Bortezomib Maintenance Therapy.

Michael Hundemer, Isabelle Herth, Tobias Meissner, Dirk Hose, Anthony D Ho, M.D., Ph.D., Kai Neben, Hartmut Goldschmidt, Mathias Witzens-Harig

Blood (2009) 114 (22): 3880.

https://doi.org/10.1182/blood.V114.22.3880.3880

Published: 2009

Journal Articles

Induction of angiogenesis by normal and malignant plasma cells

Dirk Hose, Jérôme Moreaux, Tobias Meissner, Anja Seckinger, Hartmut Goldschmidt, Axel Benner, Karène Mahtouk, Jens Hillengass, Thierry Rème, John De Vos, Michael Hundemer, Maud Condomines, Uta Bertsch, Jean-François Rossi, Anna Jauch, Bernard Klein, Thomas Möhler

Blood (2009) 114 (1): 128–143.

https://doi.org/10.1182/blood-2008-10-184226

Published: 2009

Includes: Supplemental data

Journal Articles

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

Anne Catherine Sprynski, Dirk Hose, Laurent Caillot, Thierry Réme, John D. Shaughnessy, Jr, Bart Barlogie, Anja Seckinger, Jérôme Moreaux, Michael Hundemer, Michel Jourdan, Tobias Meißner, Anna Jauch, Karène Mahtouk, Alboukadel Kassambara, Uta Bertsch, Jean François Rossi, Hartmut Goldschmidt, Bernard Klein

Blood (2009) 113 (19): 4614–4626.

https://doi.org/10.1182/blood-2008-07-170464

Published: 2009

NARROW

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma

Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment

Spatial-Temporal Genomic Analyses Reveal a Component of "Big Bang" Kinetics in Multiple Myeloma Evolution

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma,

Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications

Prognostication by miRNome-Profiling in Multiple Myeloma

A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis

Proliferation and Activation Patterns of Naïve, Memory and Regulatory T Cells in Patients with Multiple Myeloma During Thalidomide, Interferon-α and Bortezomib Maintenance Therapy.

Induction of angiogenesis by normal and malignant plasma cells

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only